In a retrospective multicenter study, approximately 54% of pediatric patients with IBD who were treated with vedolizumab achieved remission after 14 weeks, even after treatment failure with anti-TNF-α drugs (11). This evidence concerns the gene TNF and inflammatory bowel disease.